Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $8.26 Million Investment in Cencora, Inc. $COR

Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in Cencora, Inc. (NYSE:COR) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 24,465 shares of the company’s stock, valued at approximately $8,263,000.

Several other hedge funds have also recently added to or reduced their stakes in COR. Oakworth Capital Inc. acquired a new position in Cencora in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in Cencora in the fourth quarter worth approximately $27,000. Archer Investment Corp grew its position in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the last quarter. IAG Wealth Partners LLC acquired a new position in Cencora in the third quarter worth approximately $30,000. Finally, Cloud Capital Management LLC acquired a new position in Cencora in the third quarter worth approximately $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on COR shares. UBS Group lifted their price target on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Barclays lifted their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Finally, William Blair began coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $380.25.

Cencora Trading Up 1.6%

Cencora stock opened at $266.03 on Wednesday. The company has a 50 day moving average price of $310.87 and a 200 day moving average price of $338.24. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market capitalization of $51.76 billion, a price-to-earnings ratio of 20.40, a P/E/G ratio of 1.21 and a beta of 0.64.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts forecast that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.